Primary Peritoneal Cavity Cancer Clinical Trial
Official title:
A Phase II Trial Of Gemcitabine in Combination With 17-Allylaminogeldamycin (17-AAG) In Advanced Epithelial Ovarian And Primary Peritoneal Carcinoma
Phase II trial to study the effectiveness of gemcitabine hydrochloride and tanespimycin in treating patients who have recurrent advanced ovarian epithelial or primary peritoneal cavity cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and tanespimycin, work in different ways to stop tumor cells from dividing so they stop growing or die.
OBJECTIVES:
I. Determine the response rate, time to progression, and survival of patients with recurrent
advanced ovarian epithelial or primary peritoneal cavity cancer treated with gemcitabine
hydrochloride and 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) (tanespimycin).
II. Determine the toxicity of this regimen in these patients. III. Correlate the effect of
17-AAG alone on chaperone and client proteins in tumor samples and peripheral blood
mononuclear cells with response, time to progression, and survival of these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to gemcitabine
hydrochloride therapy (gemcitabine hydrochloride-naive/no prior exposure to gemcitabine
hydrochloride vs gemcitabine hydrochloride-resistant/prior exposure to gemcitabine
hydrochloride as a single agent with disease progression while on treatment). Patients
receive tanespimycin intravenously (IV) over 2 hours on days 1 and 8 during course 1 and
days 2 and 9 during subsequent courses and gemcitabine hydrochloride IV over 30 minutes on
day 7 during course 1 and days 1 and 8 during subsequent courses. Courses repeat every 21
days in the absence of disease progression or unacceptable toxicity. Patients are followed
every 3 months until disease progression and then every 6 months for up to 5 years.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
Completed |
NCT00263822 -
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
|
Phase 3 | |
Terminated |
NCT00091195 -
Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
|
Phase 2 | |
Completed |
NCT00075712 -
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00012090 -
Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum
|
Phase 2 | |
Completed |
NCT00003967 -
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
|
Phase 1 | |
Completed |
NCT00003636 -
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
|
Phase 3 | |
Completed |
NCT00019552 -
Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00003160 -
Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum
|
Phase 2 | |
Completed |
NCT00002538 -
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers
|
Phase 2 | |
Completed |
NCT00002600 -
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
|
Phase 1 | |
Active, not recruiting |
NCT00838656 -
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
|
Phase 2 | |
Completed |
NCT00398138 -
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
|
Phase 1 | |
Completed |
NCT00132067 -
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
|
Phase 2 | |
Completed |
NCT00049556 -
Gefitinib in Treating Patients With Cervical Cancer
|
Phase 2 | |
Terminated |
NCT00028782 -
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
|
N/A | |
Completed |
NCT00006942 -
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 2 | |
Completed |
NCT00003670 -
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer
|
Phase 2 | |
Completed |
NCT00003998 -
Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer
|
Phase 3 | |
Completed |
NCT00003345 -
Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
|
Phase 2 |